Clinical Trials Logo

Malignant Mesothelioma clinical trials

View clinical trials related to Malignant Mesothelioma.

Filter by:

NCT ID: NCT02580747 Recruiting - Pancreatic Cancer Clinical Trials

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Start date: October 2015
Phase: Phase 1
Study type: Interventional

RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. PURPOSE: This clinical trial is studying genetically engineered lymphocyte therapy in treating patients with Relapsed and/or Chemotherapy Refractory Advanced Malignancies.

NCT ID: NCT02349412 Completed - Depression Clinical Trials

Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers

Start date: April 2015
Phase: Phase 3
Study type: Interventional

The study intervention consists of the early integration of palliative care services into standard oncology care in an outpatient setting for patients with advanced lung and non-colorectal gastrointestinal malignancies who are not being treated with curative intent. The palliative care services provided to patients randomized to the intervention will be provided by board-certified physicians and/or advanced practice nurses and will focus on the following areas: (1) developing and maintaining the therapeutic relationship with the patients and family caregivers; (2) assessing and treating patient symptoms; (3) providing support and reinforcement of coping with advanced cancer in patients and family caregivers; (4) assessing and enhancing prognostic awareness and illness understanding in patients and family caregivers; (5) assisting with treatment decision-making; and (6) end-of-life care planning.

NCT ID: NCT02300883 Completed - Clinical trials for Malignant Mesothelioma

Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients

Start date: April 2011
Phase:
Study type: Observational

This is an observational prospective analysis of biological characteristics of malignant mesothelioma (MM) patients. Frozen and paraffin-embedded tumor specimens and pleural effusion of patients will be collected and than will be analyzed with the following analyses: 1Purification of Tumour Associated Macrophages (TAM) and tumour cells from pleural effusions. 2.Mass spectrometry analysis of TAMs and tumor cells 3.Co focal microscopy analysis of macrophages, tumour cells and specimens derived from patients.

NCT ID: NCT01655888 Recruiting - Clinical trials for Malignant Mesothelioma

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Start date: July 2012
Phase: Phase 2
Study type: Interventional

RATIONAL: Preliminary results fron the Study MESOT-TREM-2012 indicate a promising activity of tremelimumab in malignant mesothelioma (MM) patients. PURPOSE: The proposed study MESOT-TREM-2012 aims to explore the efficacy of a more intensive schedule of treatment with tremelimumab in 29 MM patients. Subjects will receive investigational product every 4 weeks (wks) for 6 doses, followed by doses every 12 wks until confirmed disease progression.

NCT ID: NCT01655225 Completed - Clinical trials for Non-small Cell Lung Cancer

A Study of LY3023414 in Participants With Advanced Cancer

Start date: July 31, 2012
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer. The study will also explore the changes to various markers in blood cells and potentially tumor cells. Finally, the study will help document any antitumor activity this drug may have. In Part A of this study, participants with advanced/metastatic cancer (including lymphoma) will receive increasing doses of LY3023414. In Part B, LY3023414 will be explored in different types of cancer, including breast and lung cancer, lymphoma and mesothelioma.

NCT ID: NCT01649024 Active, not recruiting - Clinical trials for Malignant Mesothelioma

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Start date: May 2009
Phase: Phase 2
Study type: Interventional

The study is designed to define the immunologic and clinical activity of Tremelimumab in patients with advanced mesothelioma.

NCT ID: NCT01291420 Completed - Glioblastoma Clinical Trials

Dendritic Cell Vaccination for Patients With Solid Tumors

Start date: May 3, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this study is to evaluate the immunogenicity and clinical efficacy of intradermal vaccination with autologous RNA-modified dendritic cells (DCs) - engineered to express the WT1 protein - in patients with limited spread metastatic solid tumors, i.e. breast cancers, glioblastoma grade IV, sarcomas, malignant mesothelioma and colorectal tumors. Based on the results of our previously performed phase I study with autologous WT1 mRNA-transfected DC, the investigators hypothesize that the vaccination with DC will be well-tolerated and will result in an increase in WT1-specific CD8+ T cell responses.

NCT ID: NCT01085630 Completed - Clinical trials for Malignant Mesothelioma

Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy

Start date: April 2010
Phase: Phase 2
Study type: Interventional

RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in treating patients with malignant pleural mesothelioma without progressive disease after first-line chemotherapy.

NCT ID: NCT00899613 Recruiting - Metastatic Cancer Clinical Trials

Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia

Start date: April 2007
Phase: N/A
Study type: Observational

RATIONALE: Studying levels of mesothelin and osteopontin in samples of blood from patients with mesothelioma or atypical mesothelial hyperplasia may help doctors identify biomarkers related to cancer. PURPOSE: This research study is looking at mesothelin and osteopontin as diagnostic markers in patients with mesothelioma or atypical hyperplasia.

NCT ID: NCT00898547 Terminated - Clinical trials for Malignant Mesothelioma

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

Start date: November 2005
Phase:
Study type: Observational

RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about cancer and identify biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers of angiogenesis and disease in patients with unresectable malignant mesothelioma treated on clinical trial CALGB-30107.